Determine the Prevalence of Exocrine Pancreatic Insufficiency (EPI) in Pediatric and Adult Participants With Alagille Syndrome After Liver Transplantation

August 28, 2026 updated by: Digestive Care, Inc.

A Study to Determine the Prevalence of Exocrine Pancreatic Insufficiency (EPI) in Pediatric and Adult Participants With Alagille Syndrome After Liver Transplantation

The goal of this clinical trial is to determine the prevalence of exocrine pancreatic insufficiency (EPI) in a population of pediatric and adult participants with Alagille Syndrome (ALGS) post liver transplant. During the study, participants will:

  • Consume a high fat diet
  • Keep a diary of their abdominal signs and symptoms, and stool frequency and consistency
  • Collect stool for laboratory testing

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Colorado
      • Aurora, Colorado, United States, 80045
        • Recruiting
        • Children's Hospital Colorado - Research Institute
        • Contact:
        • Principal Investigator:
          • Jacob Mark, MD
    • New York
      • New York, New York, United States, 10016
        • Not yet recruiting
        • Hassenfeld Children's Hospital at NYU Langone
        • Principal Investigator:
          • Dana Goldner, MD
        • Contact:
    • Ohio
      • Columbus, Ohio, United States, 43205
        • Not yet recruiting
        • Research Institute at Nationwide Children's Hospital
        • Contact:
        • Principal Investigator:
          • Alvin (Jay) Freeman, MD
    • Oregon
      • Portland, Oregon, United States, 97239
        • Not yet recruiting
        • Oregon Health & Science University
        • Principal Investigator:
          • Henry Lin, MD
        • Contact:
          • Research Coordinator
          • Phone Number: 503-494-1078
          • Email: royde@ohsu.edu
    • Tennessee
      • Nashville, Tennessee, United States, 37232
        • Recruiting
        • Vanderbilt University Medical Center
        • Contact:
        • Principal Investigator:
          • Saeed Mohammed, MD
    • Texas
      • El Paso, Texas, United States, 79936
        • Recruiting
        • Pediatric GI of El Paso
        • Principal Investigator:
          • Eduardo Rosas-Blum, MD
        • Contact:
    • Washington
      • Seattle, Washington, United States, 98105
        • Not yet recruiting
        • Seattle Children's Hospital - Research Institute
        • Principal Investigator:
          • Evelyn Hsu, MD
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Male and female participants ages 7-50 years inclusive with a confirmed diagnosis of ALGS status post OLT due to ALGS complications.

Description

Inclusion Criteria:

  • Male and female participants ages 7-50 years inclusive.
  • Confirmed diagnosis of ALGS
  • Status post OLT due to ALGS complications.
  • Participants currently managed with pancreatic enzyme products (PEPs) are allowed pending discontinuation of PEPs for 5 days prior to beginning the 72-hour stool collections. Participants must discontinue PEPs for the entire study period until completion.
  • Agree to adhere to a high fat diet at least 2 days prior to and during the 72-hour stool collections and monitor dietary consumption through the use of a diet diary.
  • Have a consistent caregiver for the duration of the study if applicable for enrollment of a child.
  • Capable of giving written informed consent and assent (if age appropriate).

Exclusion Criteria:

  • Surgical disruption of the enterohepatic circulation (e.g., biliary diversion).
  • Subjects with alternative etiologies of EPI (e.g., chronic panreatitis, pancreatic resection).
  • Diets high in medium-chain triglyceride (MCT) oil.
  • Use of bile acids, bile acid uptake inhibitors, lipid-binding resins, synthetic fat substitutes (e.g. Olestra), and diaper rash ointments (note that H2 antagonists and proton pump inhibitors [PPIs] are permitted if on a stable and consistent regimen throughout the duration of the study).
  • History or presence of other concomitant liver diseases such as liver transplant rejection with cholestasis, hepatitis B or C virus infection, HIV, primary sclerosing cholangitis (PSC), alcoholic liver disease, autoimmune hepatitis, metabolic-associated fatty liver disease (MASLD)/non-alcoholic steatohepatitis (NASH) or significant chronic allograft rejection.
  • Currently pregnant or breastfeeding.
  • Cancers except for in situ carcinoma or cancers treated at least 5 years prior to screening with no evidence of recurrence.
  • Participation in a clinical trial and received an investigational product within the last 30 days.
  • Use of anti-diarrheal, anti-spasmodic, and/or cathartic laxatives. Change in osmotic laxatives within the past 3 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
All Participants
Diagnostic test: Fecal Fat
coefficient of fat absorption

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dietary fat absorption
Time Frame: At the completion of the 72-hour stool collection period
Dietary fat absorption is measured by calculating the percent of fat absorption (0-100%). Higher percentage of fat absorption indicates good fat absorption.
At the completion of the 72-hour stool collection period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Digestive Care, Inc.

Collaborators

Alagille Syndrome Alliance

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 3, 2026

Primary Completion (Estimated)

August 1, 2027

Study Completion (Estimated)

August 1, 2028

Study Registration Dates

First Submitted

January 8, 2026

First Submitted That Met QC Criteria

January 9, 2026

First Posted (Actual)

January 13, 2026

Study Record Updates

Last Update Posted (Actual)

September 1, 2026

Last Update Submitted That Met QC Criteria

August 28, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 102824-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe